managing technologies

LEITAT HEALTH

Izabel Alfany, PhD
Business Development Manager
HEALTH - Strategic Projects

Horizon 2020 Health Summit-IIS La Fe

Valencia, 12 de Diciembre de 2017

Mission, vision & values

Leitat is the brand of the Acondicionamiento Tarrasense institution, a private and non-profit organization. It is recognized by the Catalan Government and by the Spanish Ministry of Science and Innovation.

Mission

Create and transfer economic, social and sustainable value to companies and entities, through research and technology processes.

Vision

Be an acknowledged technological partner in the sector, creating a corporate culture that enables sustainable growth and efficiency of actions.

Values

- Commitment
- Global Perspective
- Customer orientation
- Confidentiality
- Independence
- Dynamism
- Talent

Main figures 2016

240 professionals

260 R&D Projects

14 Nationalities

Promoting collaboration with organizations

52 Spanish / 41 International

16,5 million € revenue

Customer loyalty >97%

3 patents

Main figures 2016

56 H2020 Projects

12 GAP

15 Coordinated Projects

~ 20 million € Funding

Glass-Laser Multiplexed Biosensor

BATCure

OACTIVE

HYPOSENS

n-TRACK

Location

Terrassa
(Headquarters)

Barcelona

Vilanova del camí

Science Park of Barcelona

Santiago de Chile

Vall d'Hebron Hospital
Barcelona

La Fe Hospital
Valencia

Business Units

E+E

ENERGY & ENGINEERING

30 researchers
40 european projects
13 research contracts

ACM

APPLIED CHEMISTRY & MATERIALS

50 researchers
49 european projects
62 research contracts

INDUSTRIAL & SOCIETAL INNOVATION

CE

CIRCULAR ECONOMY

35 researchers
57 european projects
20 research contracts

STA

ADVANCED TECHNOLOGICAL SOLUTIONS

30 technicians

H&B

HEALTH & BIOMEDICINE

20 researchers
17 european projects
41 research contracts

H&B

HEALTH & BIOMEDICIME

Pharma · Food · Hospitals · Cosmetics · Veterinary

SECTORS

- NUTRITION & FOOD SCIENCES
- METABOLOMICS & BIOANALYTICS
- SKIN HEALTH & COSMETICS
- REGENERATIVE MEDICINE
- ONCOLOGY & ANGIOGENESIS
- ANTIBODY & ENGINEERING
- DIAGNOSIS & BIOSENSORS

BETTER GENITOURINARY CANCER DIAGNOSIS

ABOUT GLAM

Diagnosis and therapy monitoring

GLAM develops an innovative device for personalized diagnosis and therapy monitoring for genitourinary cancers.

Photonic biosensors

GLAM develops an integrated device based on novel label-free photonic biosensors with ultra-sensitivity, simplicity of use, portability, multiplexing and low cost.

Laser microring

GLAM capitalizes on the unprecedented sensitivity achieved using laser microring resonators to detect key biomarkers in tumor development and treatment.



Month 0 — Month 48

ACHIEVEMENTS:

- GLAM consortium already designed and generated the first prototypes of microring structures
- Antibodies have already been functionalised to the new microring structures
- Patient recruitment has started to collect urine samples
- Preliminary preclinical proof of principle with a soluble biomarkers (10) and its corresponding detecting antibody.
- Several aspects related to technical documentations are already implemented by all the consortium partners which will serve as the regulatory basis for the CE Certification and ISO 13485

glam
Glass-Laser Multiplexed Biosensor

www.glam-project.eu

Follow us on Twitter:
@GLAMproject EU

nTRACK

Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration



The main goal of nTRACK is to develop a safe, scalable and highly sensitive multimodal cell nano-imaging agent ready for first in humans. The nTRACK approach will enable non-invasive whole body monitoring, longitudinal and quantitative discrimination of living stem cells in humans using CT, MRI and PET, simultaneously.

E+E

ENERGY & ENGINEERING BUSINESS UNIT

Transport · Construction ·Packaging · Health

SECTORS



LOW CARBON ENERGY TECHNOLOGIES

SMART SYSTEMS

TECHNOLOGICAL INTEGRATION & PRODUCT DE DEVELOPMENT

ROBOTICS AUTOMATION

HYPOSENS

Minimally invasive system for faster, simpler and cheaper detection of breast cancer metastasis



OVERVIEW

Our breakthrough research will focus on the development, pre-clinical and clinical validation, and industrial demonstration of a unique all optical cancer prognostic system that will determine presence of cancer cells in the breast lymph nodes and characterize them, which correlates with presence of metastasis and bad prognosis.

The HypoSens imaging system is strategically designed to offer a minimally invasive alternative to the SLNB process with no surgery required. The device is an affordable, accurate, easy to use prognostic solution for clinicians towards, once validated, more accurate and fast diagnosis and personalised treatment options.

WHY USE THIS SYSTEM?

Label-free: The photonics system uses tumour targeted nano-confined sensors for intracellular temperature and oxygen sensing.

Non-invasive: HypoSens does not require surgery to test the lymph node status.

Fast: HypoSens will produce results in real-time.

Accurate: The nano-confined sensor particles will be able to monitor both temperature and dissolved oxygen. Coupling the nano-sensors with target antigens ensures the proper identification of the targeted tumour cells.

Safe: The prognosis system does not release any ionising radiation.

Affordable: Due to the compact nature of the imaging system, the development of HypoSens will result in a decrease in the diagnostic costs associated with metastatic breast cancer.

Simple: The device will incorporate a "plug and play" architecture which will render it easy to operate.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N. 732794.

hyposens.eu

Health Care and Ageing Society

Partners

- Philips Medical Systems Nederland B.V.
- Sapiens Steering Brain Stimulation B.V.
- Universitair Medisch Centrum Utrecht
- Stichting Kempenhaeghe
- Technische Universiteit Eindhoven
- Stmicroelectronics Srl
- Politecnico di Torino
- Universita Degli Studi di Pavia
- Universita Degli Studi Roma Tre
- Universita Degli Studi di Firenze
- Ait Austrian Institute of Technology Gmbh
- Guger Technologies Og
- Plessey Semiconductors Limited
- University of Sussex
- The Magstim Company Ltd
- Institut Mikroelektronickych Aplikaci s.r.o.
- Vysoké Učení Technické v Brne
- Acondicionamiento Tarrasense Assodacion
- G.Tec Medical Engineering Spain
- Fraunhofer-Gesellschaft zur Foerderung Der Angewandten Forschung e.V
- Mr Comp Gmbh
- Polydiagnost Gmbh

Project co-ordinator:

- Mark van Helvoort, Philips

Key project dates:

- Start: 01.06.2013
- Finish: 31.3.2016

Countries involved:

- Austria
- Czech Republic
- Germany
- Italy
- Spain
- The Netherlands
- United Kingdom

Total budget:

- € 19.9 million

DeNeCor

Devices for NeuroControl and NeuroRehabilitation

Aging of population results in an increased incidence of neurological diseases. Often, several diseases may affect the same patient, and the diagnosis techniques or the therapy for one may be incompatible with the techniques needed to address the other one.
The objective of the ENIAC JU project DeNeCor is to demonstrate the coexistence by design between implanted neuromodulation therapy devices and key diagnostic systems.



www.denecor.info

ACM

APPLIED CHEMISTRY & MATERIALS BUSINESS UNIT

Packaging · Transport · Cosmetic · Industry

SECTORS

RAW MATERIALS SYNTHESIS

- Organic
- Polymer
- Carbon
- Nanomaterials
- Interfacial chemistry

FORMULATION

- Coatings & inks
- Composites
- Cosmetics
- Detergents & Cleaners
- Lubricants

PROCESSING & VALIDATION

- Cleaning & Washing
- Coating & Printing
- Polymer Transformation
- Filtration & Separation

LEITAT
managing technologies

RESTORATION

Resorbable Ceramic Biocomposites for Orthopaedic and Maxillofacial Applications

The RESTORATION project aimed to develop resorbable bioceramic composite materials for three main applications:

- **Osteoarthritis:** The project develops functionally gradient bioceramic composite plugs for osteochondral applications.

- **Vertebroplasty and Kyphoplasty:** a new generation of vertebral cements with appropriate biological, mechanical and rheological properties are being developed.

- **Maxillofacial Fracture Fixation:** the project develops new bioceramic composites, which will possess sufficient stiffness and strength to protect and support the broken bone.

RESTORATION is a collaborative project targeted to SMEs. It applies knowledge of materials science, mechanical response, processing, clinical delivery and subsequent biological interaction in order to develop new bioceramic products for five research led SMEs partner companies





www.restoration-project.eu

CE

CIRCULAR ECONOMY BUSINESS UNIT

Biotech · Food/Feed · Agriculture · Environment

SECTORS



BOHEALTH

BOOSTING HEALTH SECTOR TO REDUCE ITS ENVIRONMENTAL IMPACT USING AN INNOVATIVE DECISION-MAKING PROCESS BASED ON LIFE CYCLE ASSESSMENT METHODOLOGY (LCA) AND LIFE CYCLE COSTING (LCC)

BOHEALTH *develops a web tool for decision making process that will contribute to environmental and economic improvement of health centres taking into account the whole life cycle.*

BOHEALTH *analyses the environmental impacts of health centres and identifies best available technologies to improve them.*

BOHEALTH achieves the following environmental **BENEFITS:**

- Savings in the consumption of materials
- Reduction of waste
- Water savings
- Energy savings
- Increase of recycling share
- Reduction of CO_2 emissions

http://www.bohealth.eu/
info@bohealth.eu

LIFE12 ENV/ES/000124

SINGULAR INITIATIVES

IAM
INTERNATIONAL ADVANCED MANUFACTURING 3D HUB

cimti
Centre per a la Integració de la Medicina i les Tecnologies Innovadores

BIP
Barcelona Institute of Packaging

HEHSc
Human & Environmental Health & Safety Centre

COLLABORATION MODEL: FLEXIBILITY

Best solution to meet your needs

JOINT INITIATIVES

CENTRE OF EXCELLENCE

EXCLUSIVE R&D LABS

GRANTED PROJECTS

CONTRACTS



1500 customers
97% customer loyalty

Leitat
Acondicionamiento Tarrasense
Tel. (+34) 93 788 23 00
Fax. (+34) 93 789 19 06

www.leitat.org
Info@leitat.org

Terrassa
C/de la Innovació, 2
08225 Terrassa (Barcelona)

Barcelona
Districte 22@
C/Pallars, 179-185
08005 Barcelona

Barcelona
Parc Científic de Barcelona
C/Baldiri Reixac, 15-21
08028 Barcelona

Vilanova del Camí
Centre d'Innovació Anoia
C. dels Impressors, 12
08788 Vilanova del Camí (Barcelona)

VHIR - Vall d'Hebron Institut de Recerca
Edificio Mediterránea, Hospital Vall d'Hebrón
Passeig de la Vall d'Hebron, 119-129
08035 Barcelona

Biopolo La Fe
Hospital La Fe, Torre A, Planta Baja
Avenida Fernando Abril Martorell, 106
46026 Valencia

SOCIAL NET:

innpulso
Ciudad de la Ciencia y la Innovación
Terrassa
Vilanova del camí

LEITAT
managing technologies

Izabel Alfany, PhD – ialfany@leitat.org
Business Development Manager
HEALTH – Strategic Projects